Fosmetpantotenate

• CAT Number: I006849
• CAS Number: 1858268-66-2
• Molecular Formula: C20H31N2O9P
• Molecular Weight: 474.447
• Purity: ≥95%
• Synonyms: Fosmetpantotenate; RE-024; RE024; RE 024.;Dimethyl 8-hydroxy-2,7,7-trimethyl-4,9-dioxo-4-phenoxy-5-oxa-3,10-diaza-4-lambda5-phosphatridecanedioate, mixture of (2S,4R,8R) and (2S,4S,8R) epimers
• Target: immunomodulator
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: methyl (2S)-2-[[[(3R)-3-hydroxy-4-[(3-methoxy-3-oxopropyl)amino]-2,2-dimethyl-4-oxobutoxy]-phenoxyphosphoryl]amino]propanoate
• InChI: InChI=1S/C20H31N2O9P/c1-14(19(26)29-5)22-32(27,31-15-9-7-6-8-10-15)30-13-20(2,3)17(24)18(25)21-12-11-16(23)28-4/h6-10,14,17,24H,11-13H2,1-5H3,(H,21,25)(H,22,27)/t14-,17-,32?/m0/s1
• InChIKey: HUWUHKIPYXWUPN-YVRVQSMLSA-N
• SMILES: CC(C(=O)OC)NP(=O)(OCC(C)(C)C(C(=O)NCCC(=O)OC)O)OC1=CC=CC=C1

Fosmetpantotenate (CAT: I006849), also known as RE-024, is an immunomodulator that shows promise in the treatment of Pantothenate Kinase Associated Neurodegeneration (PKAN). PKAN is a rare neurodegenerative disorder characterized by the accumulation of iron in specific areas of the brain. Fosmetpantotenate acts by targeting the underlying metabolic dysfunction in PKAN, specifically the impairment of the coenzyme A biosynthesis pathway. By restoring coenzyme A levels, fosmetpantotenate aims to alleviate the symptoms and slow the progression of the disease. Clinical trials are underway to further evaluate its safety and efficacy in PKAN patients.

Reference

1.Elbaum, Daniel, et al. "Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: mechanism of action and efficacy in nonclinical models." PloS one 13.3 (2018): e0192028.